Randomized, Phase II Study of the Insulin-Like Growth Factor-1 Receptor Inhibitor IMC-A12, With or Without Cetuximab, in Patients With Cetuximab- or Panitumumab-Refractory Metastatic Colorectal Cancer | Zendy

Diane ReidyLagunes | Zendy; Efsevia Vakiani | Zendy; Marwan Fakih | Zendy; Muhammad Wasif Saif | Zendy; J. Randolph Hecht | Zendy; Noah Goodman-Davis | Zendy; Ellen Hollywood | Zendy; Jinru Shia | Zendy; Jonathan Schwartz | Zendy; Kumari Chandrawansa | Zendy; Aruna Dontabhaktuni | Zendy; Hagop Youssoufian | Zendy; David B. Solit | Zendy; Leonard B. Saltz | Zendy

Open Access

Randomized, Phase II Study of the Insulin-Like Growth Factor-1 Receptor Inhibitor IMC-A12, With or Without Cetuximab, in Patients With Cetuximab- or Panitumumab-Refractory Metastatic Colorectal Cancer

Author(s) -

Diane ReidyLagunes,

Efsevia Vakiani,

Marwan Fakih,

Muhammad Wasif Saif,

J. Randolph Hecht,

Noah Goodman-Davis,

Ellen Hollywood,

Jinru Shia,

Jonathan Schwartz,

Kumari Chandrawansa,

Aruna Dontabhaktuni,

Hagop Youssoufian,

David B. Solit,

Leonard B. Saltz

Publication year - 2010

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2010.30.4154

Subject(s) - cetuximab , medicine , kras , panitumumab , colorectal cancer , epidermal growth factor receptor , oncology , gastroenterology , refractory (planetary science) , phases of clinical research , cancer , clinical trial , physics , astrobiology

To evaluate the safety and efficacy of IMC-A12, a human monoclonal antibody (mAb) that blocks insulin-like growth factor receptor-1 (IGF-1R), as monotherapy or in combination with cetuximab in patients with metastatic refractory anti-epidermal growth factor receptor (EGFR) mAb colorectal cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research